Drug-eluting stents below the knee
M Bosiers1, K Deloose, J Callaert
1Department of Vascular Surgery, A.Z. Sint-Blasius, Dendermonde, Belgium. marc.bosiers@telenet.be
The Journal of Cardiovascular Surgery
|April 5, 2011
Summary
Drug-eluting stents (DES) improve long-term patency in below-the-knee arteries by preventing thrombosis and intimal hyperplasia. Evidence supports primary DES placement for short lesions, enhancing treatment strategies.
Area of Science:
- Vascular surgery
- Interventional cardiology
- Biomedical engineering
Background:
- Stent implantation in below-the-knee (BTK) arteries faces challenges due to early thrombosis and late intimal hyperplasia, impacting long-term patency.
- Drug-eluting stent (DES) technology aims to mitigate these issues, potentially improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of DES in improving long-term patency rates in small diameter BTK arteries.
- To provide level 1 evidence for the use of DES in infrapopliteal vasculature.
Main Methods:
- Prospective, randomized, controlled studies (DESTINY and ACHILLES) were analyzed.
- Outcomes of DES implantation in short lesion lengths within the infrapopliteal arteries were assessed.
Main Results:
- DES implantation in short BTK lesions demonstrated favorable outcomes.
- High primary patency rates were achieved with DES in the studied population.
Conclusions:
- Primary DES placement is a recommended treatment strategy for short below-the-knee lesions.
- DES technology shows promise in improving long-term patency and addressing challenges in BTK interventions.
